Bristol-Myers Squibb Co. (NYSE:BMY)

Prescription drugs

Top Credit Suisse Major Pharma Stock Picks to Buy

Considering the health care sector has been on fire for the first quarter of 2015, analysts are putting more value in biotechs and big pharmaceuticals. Credit Suisse is no different. ...
Read Full Story »
health care

Will Schizophrenia and Bipolar Patients Trust Generic Abilify?

The trend towards generic drugs is nothing new. It does not matter if a drug has billions of dollars in annual sales or not, when they go off patent generics ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: GE, IBM, Bristol-Myers, Encana, Halliburton, Rio Tinto, WhiteWave and More

Stocks were indicated up on Tuesday, even after Monday's big gains. The trend that is nearing four years old now is that investors keep buying stocks on weakness. 24/7 Wall ...
Read Full Story »
Pills

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

One thing investors look for in an aging bull market, especially one trading near all-time highs, is rising earnings. That is the only way to justify multiples that creep up ...
Read Full Story »
Prescription drugs

4 Big Pharmaceutical Stocks to Buy for the Rest of 2015

While most people consider big pharmaceutical stocks very defensive, the fact of the matter is that they offer investors terrific growth and income possibilities, which can lead to outstanding total ...
Read Full Story »
generic drugs

4 Pharmaceutical Stocks to Buy for Outperformance in 2015

It is a nice change sometimes when the prognosticators on Wall Street, who tend to follow each other's lead, are not only right, but investors come out on top. Almost ...
Read Full Story »
Pills

4 Top Pharmaceutical Stocks to Buy for Market Safety

Tuesday's big downward move reminded everybody that while things look encouraging for the stock market long term, momentum stocks tend to get absolutely eviscerated when a big volatility jump helps ...
Read Full Story »
DNA

Is Rigel Getting Enough From Bristol-Meyers?

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Bristol-Myers Squibb Co. (NYSE: BMY) announced Monday morning that they have entered into a collaboration agreement regarding the development and commercialization of cancer immunotherapies. ...
Read Full Story »
145922793

5 Top Credit Suisse Health Care Stock Picks to Buy for 2015

As one of the top sectors in the S&P 500 in 2014, health care has one factor that almost always makes it a reasonably safe place to invest in. The ...
Read Full Story »
Pills

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today. ...
Read Full Story »
Pills

5 Top Pharmaceutical Stock Picks for 2015

After an outstanding 2014, the health care sector could be primed for yet another solid performance in 2015. While many analysts on Wall Street are very positive on the group, ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Applied Materials, Broadcom, Cisco, Genworth, SanDisk and More

Stocks were indicated higher on Thursday morning and the market is still challenging all-time highs. Investors have proven day after day that they will buy stocks when they are discounted ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AmEx, Baidu, BofA, Citi, Lululemon, Netflix, Tiffany and More

Stocks were getting smacked lower again on Thursday morning. While that elusive 10% market correction is closer and closer to fruition, investors still are willing to keep buying value and ...
Read Full Story »
biotech

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

One sad thing for almost every citizen in the United States is that at one point almost all of us will either have cancer or have a friend or relative ...
Read Full Story »
biotech

3 Likely Biotech Buyout Candidates

The pharmaceutical business is a difficult one, because patent expiration and competition are always omnipresent factors. Obviously major companies like to keep large research and development projects moving at full ...
Read Full Story »